Expanding access to quality, affordable maternal health medicines is critical to making progress in reducing maternal mortality. However, significant challenges often impede such access. Chief among them is a lack of data on the needs, gaps, systems and financing for maternal health medicines.
This report, prepared for the United Nations Commission on Commodities for Women and Children’s Health, provides a review of the current conditions and available evidence on maternal health medicines, specifically Oxytocin and Misoprostol to prevent post-partum haemorrhage and magnesium sulfate, considered the safest, most effective, and lowest-cost medication for treating pre-eclampsia and eclampsia.
The report also includes 11 priority issues for actions
Under the auspices of the United Nations Secretary-General’s Every Woman Every Child initiative, the Commission on Life-Saving Commodities for Women and Children advocates at the highest levels for the increased availability, affordability and accessibility of essential but underutilized commodities for maternal and child health.